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Telomeric regions of mammalian chromosomes contain sup-
pressive TTAGGG motifs that inhibit several proinflammatory
and Th1-biased immune responses. Synthetic oligodeoxynucle-
otides (ODN) expressing suppressive motifs can reproduce the
down-regulatory activity of mammalian telomeric repeats and
have proven effective in the prevention and treatment of several
autoimmune and autoinflammatory diseases. Endotoxin-in-
duced uveitis (EIU) is an established animalmodel of acute ocu-
lar inflammation induced by LPS administration. Augmented
expression of proinflammatory cytokines/chemokines such as
TNF, IL-6, andMCP1 and bactericidal nitric oxide production
mediated by LPS contribute to the development of EIU. Sup-
pressing these mediators using agents that are devoid of unde-
sirable systemic side effects may help prevent the development
of EIU. This study demonstrates the selective down-regulatory
role of suppressive ODN after (i) local or (ii) systemic treatment
in EIU-induced rabbits and mice. Our results indicate that sup-
pressive ODN down-regulate at both the transcript and protein
levels of several proinflammatory cytokines and chemokines as
well as nitric oxide and co-stimulatory surface marker mole-
cules when administrated prior to, simultaneously with, or even
after LPS challenge, thereby significantly reducing ocular
inflammation in both rabbit and mouse eyes. These findings
strongly suggest that suppressive ODN is a potent candidate for
the prevention of uveitis and could be applied as a novel DNA-
based immunoregulatory agent to control other autoimmune or
autoinflammatory diseases.
DNA and RNA are the essential components of all living
organisms. Accumulated evidence strongly suggests that these
nucleic acids havemultiple and complex effects on the immune
system and aremore than a blueprint of life (1, 2). On one hand,
due to their high unmethylated CpGmotif frequency, bacterial
DNAs are recognized as “non-self” via TLR9 (Toll-like receptor
9) and trigger an innate immune response characterized by the
proliferation and maturation of B cells, natural killer cells, and
plasmacytoid dendritic cells and the secretion of T-helper
1-type cytokines, chemokines, and/or multivalent immuno-
globulins (3–8). On the other hand, telomeric regions of mam-
malian chromosomes contain suppressive TTAGGG motifs
that can inhibit several TLR-dependent and TLR-independent
Th1-mediated immune responses. Of note, these motifs are
underrepresented in the prokaryotic genome. Synthetic single-
stranded oligodeoxynucleotides (ODN)3 containing repetitive
TTAGGG motifs mimic this effect (1, 9–11). Previous studies
revealed that deleterious inflammatory responses to a host can
be down-regulated by suppressive ODN. In vitro, suppressive
ODN inhibits the production of several proinflammatory cyto-
kines and chemokines induced by bacteria (1, 12–14). Further-
more, in vivo suppressive ODN administration reduces the fre-
quency and severity of several autoimmune and inflammatory
diseases such as arthritis, systemic lupus erythematosus, pul-
monary inflammation, toxic shock, silicosis, and experimental
autoimmune encephalomyelitis (10, 15–21).
Uveitis is an ophthalmic disorder that causes vision loss in
developed countries (22, 23) and is characterized by acute,
recurrent, or persistent ocular inflammation, the breakdown of
the blood-ocular barrier, and infiltration of leukocytes (24). The
underlying causes of uveitis can vary. For example, acute ante-
rior uveitis is often associated with (i) Behcet disease, (ii) Reiter
syndrome, and (iii) ankylosing spondylitis, as well as other sys-
temic inflammatory diseases (25).
Endotoxin-induced uveitis (EIU) is an established animal
model of acute ocular inflammation. It is triggered by the
administration of LPS, which is a component of the Gram-neg-
ative bacterial outer membrane (26). A ligand for TLR4, LPS
enhances the expression of various proinflammatory cytokines
and chemokines such as IL-6 (27, 28), TNF (29), and MCP1
(monocyte chemoattractant protein 1) (30) and the production
of nitric oxide. All of these mediators contribute to the break-
down of the blood-ocular barrier and infiltration of leukocytes,
resulting in the development of EIU (26). It has been shown that
suppressing proinflammatory cytokines, including IL-6, TNF,
MCP1, and inducible nitric-oxide synthase (iNOS), retards if
not prevents the development of EIU (31). Conventional drugs
used to control these concerted inflammatory activation are
mainly immunosuppressive in character and are associated
with undesirable systemic side effects (24). It is of the utmost
importance to develop effective, less toxic agents that selec-
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tively block proinflammatory immune activation while elimi-
nating the unwanted systemic side effects.
To date, the inhibitory effect of suppressive ODN on LPS-
mediated EIU at both the local and systemic levels has not been
studied by others. In this study, a very aggressive form of exper-
imental uveitis was initiated via endotoxin administration. We
investigated whether the suppressive ODN “A151” can inhibit
the induction and development of ocular inflammation (before
or at the time of LPS insult or even 2 h after LPS treatment) and
help to reduce the symptoms of EIU in rabbits and mice. Our
results revealed, for the first time, that A151 is capable of down-
regulating the mRNA expression and protein levels of several
potentially pathologic chemokines and cytokines at both the
local and systemic levels. Consequently, suppressive ODN
mimicking telomeric DNA offers a novel nucleic acid-based
immunotherapeutic agent to control overexuberant undesir-
able immune responses such as seen in autoimmune and auto-
inflammatory diseases.
EXPERIMENTAL PROCEDURES
Materials—All cell culture medium components were from
HyClone. Cytokine pairs for ELISAs were from Endogen.
LPS (isolated from Escherichia coli) was obtained from
Sigma. The phosphorothioate-modified suppressive ODN
A151 (24-mer, 5-(TTAGGG)4-3) and control ODN (24-
mer, 5-(TTACCC)4-3) were obtained from Alpha DNA
(Montreal, Canada). TRIdity G (AppliChem GmbH, Darms-
tadt, Germany) was used for RNA isolation. cDNAs were
synthesized using a DyNAmoTM cDNA synthesis kit
(Finnzymes, Espoo, Finland) according to the manufac-
turer’s protocol. DyNAzymeTM PCR Master Mix was used
for PCRs.
Maintenance of Animals—Adult female BALB/c mice and
adult New Zealand rabbits were used for the experiments. The
animals were kept in the animal holding facility of the Depart-
ment of Molecular Biology and Genetics at Bilkent University
under controlled conditions at 22 °C with 12-h light and 12-h
dark cycles. They were provided with unlimited access of food
and water.
Induction of Endotoxin-induced Uveitis—Specific pathogen-
free 10-week-old female BALB/c mice were injected intraperi-
toneally with 25, 50, 100, or 200 g of LPS in 200 l of PBS
and/or suppressive ODN.Mice were killed at the end of clinical
evaluation. Both eyes were enucleated and used for cytokine
expression assays. Spleens were removed and split in two;
splenocytes were incubated on tissue culture plates for 6, 12,
and 24 h; and supernatants were collected for cytokine deter-
mination by ELISA. IL-6 was measured as an indicator of EIU
response. The other half of the spleen was used to extract total
RNA for further cytokine/chemokine gene transcript expres-
sion analysis by RT-PCR. In another experiment, rabbits (three
to four animal/group,1500 g each; housed in theAnkaraHos-
pital animal facility) were separated into different treatment
groups, and EIUwas initiated via intraocular LPS injection (100
g) with or without suppressive ODN treatment. Eyes were
removed, and further analyses as described for mice were
conducted.
Clinical Evaluation and Histopathological Investigation—Ani-
mals were subjected to blind investigation by an ophthalmolo-
gist under a dissectionmicroscope 18–24 h after injection, cor-
responding to the time of maximal severity of EIU. Clinical
ocular inflammation was graded on a scale from 0 to 4 for each
animal described previously (32): no sign of inflammation  0;
discrete inflammation in iris and conjunctiva  1; dilatation of
iris and conjunctiva vessels  2; hyperemia in iris associated
with Tyndall effect in anterior chamber  3; in addition to the
signs in scale 3, synechia or fibrin is formed  4 (32). For his-
topathological investigations, enucleated eyeswere fixed in 10%
formalin for 24 h, washed with running tap water for 1 h, and
placed in 60% ethyl alcohol for an extra 3 h. Eyes were embed-
ded in paraffin, whichwas sectioned and stainedwith hematox-
ylin and eosin. Sections were examined blindly by a his-
topathologist, using score systems of severity ranging from 0 to
4. Focal non-granulomatous monocytic infiltration in the cho-
roid, the ciliary body and retina were scored as 0.5. Retinal
perivascular infiltration andmonocytic infiltration in the vitre-
ous were scored as 1. Granuloma formation in the uvea and
retina and the presence of occluded retinal vasculitis alongwith
photoreceptor folds, serous detachment, and loss of photore-
ceptor were scored as 2. In addition, the formation of Dalen-
Fuchs nodules (granuloma at the level of the retinal pigmented
epithelium) and the development of subretinal neovasculariza-
tion were scored as 3 and 4 according to the number and size of
the lesions (33).
Cytokine and IgM ELISAs and NO Assays—Immulon 2 HB
microtiter plates (Thermo Scientific) were coated with anti-
cytokine or anti-IgM antibodies (BD Pharmingen) and then
blocked with PBS and 1% BSA (1, 34). Serially diluted stand-
ards and culture supernatants or mouse sera were added to
these plates for 2 h. Cytokine was detected using biotinylated
anti-cytokine antibody followed by phosphatase-streptavi-
din (Perbio), whereas bound IgM was detected using phos-
phatase-conjugated anti-IgM antibodies (Southern Biotech-
nology Associates, Birmingham, AL) as described (1). Nitric
oxide detection by theGriessmethodwas conducted onmurine
peritoneal exudate cells (106/ml) after 12–36 h of ex vivo incu-
bation as described by the supplier (Promega).
Analysis of Cell-surface Molecule Expression by FACS—2 
106 spleen cells/ml were isolated from 24-h post-treated mice.
Cells were washed, fixed, and co-stained with one of the phy-
coerythrin-labeled anti-CD40, anti-CD86, and anti-ICAM-1
and FITC-labeled cell-specific antibodies (i.e. CD11c for den-
dritic cells, CD11b for macrophages, and B220 for B cells (BD
Pharmingen)) for 30 min at room temperature. Following
washing, they were studied using a FACSCalibur (BD Bio-
sciences) and analyzed with CellQuest Pro software.
Cytokine and Chemokine RT-PCR—Animals were injected
with LPS and/or suppressive ODN. Total RNA was extracted
from the eyes or spleens of the mice 4–6 h later (or from the
irises or corneas of the rabbits), reverse-transcribed, and ampli-
fied to obtain cDNA in a standard PCR for 30 cycles using
primers for mouse- or rabbit-specific target genes (Table 1) as
described previously (1, 34). PCR-amplified material was sepa-
rated on 1.5% agarose gels and visualized under UV light after
ethidium bromide staining.
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Statistical Analysis—Assays were performed in triplicate on
at least three to five different cell preparations. Statistical sig-
nificance between untreated (or control) and treated groups
was evaluated using Student’s t test.
RESULTS
EIU is an established animal model of acute ocular inflam-
mation. It is induced by either systemic or intravitreal
administration of LPS, the major component of Gram-neg-
ative bacteria. LPS acts through the TLR4-triggering proin-
flammatory signaling cascade. The expression of Th1 cyto-
kines and chemokines, including IL-6, IL-1, and MIP3
(macrophage inflammatory protein 3), contributes to the
development of EIU.
This study was performed with 82 mice and 26 rabbits. Initial
experiments were conducted to optimize the induction of EIU
(supplement Fig. 1). For themouse experiments, systemic admin-
istration of LPS doses between 25 and 100 g/mouse were suffi-
cient to induce uveitic eyes within 24 h as judged by clinical and
histopathological investigations (supplement Figs. 1 and 2). For
the rabbit experiments, intraocular 100-g LPS injection was
found to be optimal to induce EIU. Following local or intraperito-
neal LPS and or suppressive ODN administration, rabbit and
mouseeyeswere removed, andRNAs fromthe irises, vitreous, and
corneas of the rabbit eyes were obtained. PCR was run with the
cDNAfromeach sample, and themRNAlevels of IL-6, IL-15, IP10
(interferon--inducible protein 10), iNOS,MIP1, IL-18,MIP3,
CXCL16 (CXC chemokine ligand 16), MIP1, and IL-1 were
monitored. In addition, 24 h post-LPS and/or A151 treatment,
splenocyte suspensions were incubated ex vivo for 6–24 h,
and IgM, IL-6, IL-10, IL-12, and IFN levels from the super-
natants were determined by ELISA. FACS analyses were
conducted on spleen cells to monitor co-stimulatory/surface
marker molecule expressions.
The results indicated that in rabbits, suppressive ODN
administered before or after 100-g LPS treatment or co-in-
jected with LPS significantly down-regulated the expression of
IL-1message from the iris (Fig. 1A). In cornea, IL-6was down-
regulated when suppressive ODN was given before or simulta-
neously with LPS administration (Fig. 1B). There was no sig-
nificant inhibitory effect when A151 was given post-LPS
treatment. In all these experiments, the mRNAmessage reduc-
tion was suppressive ODN-dependent because control ODN
administration did not show any benefit for alleviation of LPS
reactogenicity.
TABLE 1
Oligonucleotide PCR primers used in mouse or rabbit experiments
m, mouse; rb, rabbit.
Primer Forward Reverse Product
bp
m-actina GTATGCCTCGGTCGTACCA CTTCTGCATCCTGTCAGCAA 450
mIP10a GCCGTCATTTTCTGCCTCAT GCTTCCCTATGGCCCTCATT 127
miNOSa CAGCTGGGCTGTACAAACCTT CATTGGAAGTGAAGCGTTTCG 95
mMIP1b ACCATGACACTCTGCAACCA AGGCATTCAGTTCCAGGTCA 238
mIL-5a AGCACAGTGGTGAAAGAGACCTT TCCAATGCATAGCTGGTGATTT 117
mIL-15a CATCCATCTCGTGCTACTTGTGTT CATCTATCCAGTTGGCCTCTGT 126
mIL-18b GATCAAAGTGCCAGTGAACC ACAAACCCTCCCCACCTAAC 384
mMCP1b AGGTCCCTGTCATGCTTCTG TCTGGACCCATTCCTTCTTG 249
mMIP3b CGTCTGCTCTTCCTTGCTTT CCTTTTCACCCAGTTCTGCT 250
mCXCL16b CCTTGTCTCTTGCGTTCTTC GGTTGGGTGTGCTCTTTGTT 384
mMIP1b CCAGCTCTGTGCAAACCTAA CTGTCTGCCTCTTTTGGTCA 250
rbGAPDHc TCACCATCTTCCAGGAGCGA CACAATGCCGAAGTGGTCGT 319
rbIL-6c GCTCCTGGTGGTGGCTAC GGGTGGCTTCTTCATTCAAA 450
rbIL-1c GCCGATGGTCCAATTACAT ACAAGACCTGCCGGAAGCT 121
a Taken from Ref. 43.
b In house-designed primers.
c Taken from Ref. 44.
FIGURE 1. Suppressive A151 ODN administration after LPS challenge sig-
nificantly down-regulates IL-1 and IL-6 expression in the iris and cor-
nea, respectively. Rabbits were injected intraocularly with 100 g of LPS and
250 g of suppressive ODN. The average of densitometric measurements of
four animals for IL-1 mRNA from iris (A) and IL-6 mRNA from cornea (B) is
shown. Insets are the representative gel image of each group labeled from
untreated to A151 and then LPS as 1 to 6. *, p  0.05; **, p  0.01 between
LPS-treated and A151 ODN-co-administered groups.
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In the murine EIU model, mice tolerated up to 100-g LPS
intraperitoneal treatment. Doses 150 g caused animals to
succumb to endotoxin treatment. The mouse experiments
were conducted with three doses of LPS: 25, 50, and 100 g.
SuppressiveA151ODNand controlODN (2 h before and at the
time of LPS injection and 2 h after LPS treatment) were used in
the range of 100–250 g. Although in rabbits, the injection of
ODN and endotoxin was intraocular, in mice, injections were
given intraperitoneally in 200 l of PBS.
The results showed that when 250 g of suppressive ODN
was administered before LPS injection (2 h), it significantly
down-regulated the expression of IP10, iNOS, MIP3,
CXCL16, and MIP1 in the 100-g LPS-injected mouse EIU
model (Figs. 2, A and B). Other cytokines such as MIP1 and
IL-18 also showed substantial but insignificant down-regula-
tion at these doses (data not shown). To understand the sys-
temic effect of suppressive A151, IL-6 secreted from murine
splenocytes after ex vivo incubation for up to 24 h in culturewas
monitored by ELISA (Fig. 3). Our results revealed that suppres-
sive ODNwas able to reduce 65% of the secreted IL-6 (430 
70 and 135 55 ng/ml for LPS andA151 LPS groups, respec-
tively). Co-administration of suppressiveODNwith LPS signif-
icantly decreased cytokinemRNA levels in vivoor cytokine pro-
duction in ex vivo spleen cells (p  0.01) (Figs. 2 and 3). These
effects were attributable to the activity of suppressive motifs
because control ODN did not reduce the cytokine production
elicited by co-administered LPS (Figs. 1–3).
The (TTAGGG)4 multimers inhibited LPS-dependent up-
regulation of co-stimulatory and surface marker molecules on
antigen-presenting cells (CD40, CD86, and ICAM-1), IgM pro-
duction by B cells, and NO release from peritoneal macro-
phages (p  0.01) (Fig. 4). Furthermore, co-administration of
LPS (50g)withA151ODN (250g) inhibited65%of several
immunoregulatory and inflammatory cytokines (i.e. IL-6,
IL-10, and IL-12; p  0.001) (Fig. 4). This reduction reached
85% for IFN (176 29 and 26 15 ng/ml for LPS andA151
LPS groups, respectively).
DISCUSSION
In this study, we examined the effect of synthetic telomeric
repeat units (suppressive A151 ODN) localized at the end of
mammalian chromosomes on EIU, which is an established ani-
mal model of acute ocular inflammation in both mouse and
rabbit models. The results indicated that suppressive ODNwas
able to down-regulate the expression and protein levels of sev-
eral proinflammatory and immunoregulatory cytokines/che-
mokines at local and systemic levels when administrated (i)
prior to, (ii) simultaneously with, or (iii) even after LPS chal-
lenge (Figs. 2–4).
FIGURE 2. A, suppressive A151 ODN treatment after 100-g LPS challenge
significantly down-regulates IP10, MIP3, iNOS, MIP1, and CXCL16 expres-
sion levels in the eyes of mice. Mice were injected intraperitoneally with 100
g of LPS and 250 g of suppressive ODN and killed 18 h after injection. *, p 
0.05; **, p  0.01 between LPS-treated and LPS  A151 ODN-co-administered
groups. B, representative gel image.
FIGURE 3. Suppressive A151 ODN administration significantly sup-
presses IL-6 release from murine splenocytes. Mice were injected intrap-
eritoneally with 100 g of LPS and 250 g of suppressive or control ODN as
further indicated. Spleen cells were removed (24 h post injection) and incu-
bated 6 –24 h, and supernatants were collected for cytokine ELISA. IL-6 was
measured as an indicator of EIU response. *, p  0.05, between LPS and LPS 
A151 groups.
FIGURE 4. Inhibitory effect of suppressive ODN on LPS-mediated immune
activation. The levels of CD40, CD86, and ICAM-1 expression (mean fluores-
cence intensity) were determined by FACS 24 h after in vivo injection of LPS or
LPS plus A151 (50 g of LPS and 250 g of ODN). IL-6, IL-10, IL-12, IFN, and
IgM levels in culture supernatants were determined by ELISA following 36 h of
ex vivo incubation. The Griess method was used to detect nitric oxide in
isolated peritoneal exudate cells supernatants 24 h post-treatment. % Sup-
pression was calculated by the following formula: (1 	 ((activation by LPS 
suppressive ODN) 	 (background)/(activation by LPS  control ODN) 	
(background)))  100.
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Compared with local injection of (intraocular) LPS and/or
LPS- and control ODN-treated rabbits, suppressive ODN-ad-
ministrated animals exhibited reduced levels of IL-1 and IL-6
expression in the iris and cornea, respectively. In the mouse
model, the results revealed that pretreatment with 250 g of
suppressive ODN reduced the expression of IP10, iNOS,
MIP1, IL-18, MIP3, CXCL16, and MIP1 in 100-g LPS-
injected mice. In another experiment, with different doses of
suppressive ODN and LPS, suppressive ODN also down-regu-
lated the expression of MCP1, which is an important chemo-
kine formonocyte chemoattraction (data not shown). The sup-
pressive action of this class of ODNwas not only on the mRNA
levels of several Th1-type cytokines and chemokines but also on
the secreted protein level. ELISA experiments showed that sup-
pressive ODN pre- and post-treatments significantly dimin-
ished IL-6 secretion at 6 and 24 h; simultaneous administration
of suppressive ODN also reduced IL-6 production.
Several studies indicated that suppressing proinflammatory
cytokines, including IL-6, TNF, MCP1, and iNOS, prevents
the development of EIU (26, 29, 30, 31). Here, we have shown
that either local (intraocular) or systemic (intraperitoneal)
administration of suppressive A151 ODN can significantly
reduce several proinflammatory cytokines and chemokines
even 2 h after in vivo LPS challenge.
Corticosteroids and chemotherapeutic agents are currently
in use in uveitis therapy (35). However, long-term treatment
with these drugs may have grave side effects such as increased
intraocular pressure (36) and cytotoxicity (37) and thus limit
their use (25, 33, 35). Therefore, a new therapeutic strategy is
urgently needed (38, 39). Themechanism of action of this novel
ODN-based immunosuppressive drug candidate is currently
unknown. Previous studies revealed that suppressive ODN can
inhibit immune response by blocking the stimulatory effects of
CpGmotifs (1, 15). It also has been shown by Shirota et al. (10)
that suppressive A151 ODN can also protect mice from lethal
endotoxic shock that is induced by LPS. It has been shown that
suppressive ODN can also inhibit several signal transduction
cascades related to the production of Th1 cytokines such as
IFN and IL-12 by binding and inhibiting the phosphorylation
of STAT1 (signal transducer and activator of transcription 1)
and STAT4 proteins (10, 13). Our study has demonstrated that
suppressive ODN can block immune responses mediated by
endotoxin in the eye (an immune privileged site), an established
animalmodel of acute ocular inflammation. Recently, Fujimoto
et al. (40) reported that suppressive A151 ODN can inhibit
ocular inflammation in two murine models, IRBP (interpho-
toreceptor retinoid-binding protein)-induced experimental
autoimmune uveitis and adoptively transferred ocular in-
flammation. These forms are antigen-driven and, compared
with LPS, are significantly less aggressive forms of experimental
uveitis models. The control of LPS-mediated EIU at both the
local and systemic levels has not been studied by others and
increases the breadth of the suppressive ODN-mediated ther-
apy for the eye. Collectively, these observations support the
provocative possibility that the evolutionary expansion of
TTAGGG repeats in telomeres, in addition to known proper-
ties such as, protecting genomic DNA from degradation, and
chromosome capping (41, 42)may also be linked to their ability
to down-regulate sustained/pathologic microbe-associated
molecular pattern-induced immunity. In conclusion, we have
provided evidence that suppressive A151ODN is able to signif-
icantly reduce the ocular inflammatory responses in both rabbit
and murine EIU models.
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